<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00572611</url>
  </required_header>
  <id_info>
    <org_study_id>BILA 459-13</org_study_id>
    <secondary_id>EudraCT Number: 2007-003373-12</secondary_id>
    <secondary_id>CR Study Number: 186781</secondary_id>
    <nct_id>NCT00572611</nct_id>
  </id_info>
  <brief_title>Human Mass Balance Study With Bilastine</brief_title>
  <official_title>A Phase I Study to Investigate the Absorption, Metabolism and Excretion of [14C]-Bilastine Following Oral Administration to Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Faes Farma, S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Charles River Clinical Services Edinburgh Ltd and CR Laboratories Preclinical Services Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>MDS Pharma Services Switzerland AG</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Faes Farma, S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to define the absorption and excretion kinetics of&#xD;
      bilastine in man following oral administration, and to investigate the nature of the&#xD;
      metabolites present in plasma and excreta. The secondary objective of the study is to assess&#xD;
      the safety and tolerability of bilastine&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Endpoints are: Whole blood and plasma concentrations of total radioactivity and&#xD;
      parent drug. Urine and faecal recovery of total radioactivity. Characterisation and&#xD;
      identification of metabolites in plasma, urine and faeces.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Whole blood and plasma concentrations of total radioactivity and parent drug</measure>
    <time_frame>168-216 h after dosing, depending on the radioactivity recovery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine and faecal recovery of total radioactivity</measure>
    <time_frame>168-216 h after dosing, depending on the radioactivity recovery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterisation and identification of metabolites in plasma, urine and faeces</measure>
    <time_frame>168-216 h after dosing, depending on the radioactivity recovery</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of 20 mg [14C]-bilastine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]-bilastine</intervention_name>
    <description>Single oral dose of 20 mg [14C]-bilastine. 1 capsule. 1 day dosing only</description>
    <arm_group_label>I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  No clinically important abnormal physical findings.&#xD;
&#xD;
          -  No clinically significant abnormalities in the results of laboratory evaluation.&#xD;
&#xD;
          -  Normal ECG.&#xD;
&#xD;
          -  Normal supine blood pressure and heart rate.&#xD;
&#xD;
          -  Body weight between 50 and 100 kg and body mass index between 18 and 30 kg/m2.&#xD;
&#xD;
          -  Able to communicate well with the investigator and to comply with the requirements of&#xD;
             the entire study.&#xD;
&#xD;
          -  Provision of written informed consent to participate.&#xD;
&#xD;
          -  Subjects must agree to use an adequate method of contraception during the study and&#xD;
             for 12 weeks after dosing.&#xD;
&#xD;
          -  Subjects must have a negative urine screen for drugs of abuse.&#xD;
&#xD;
          -  Subjects must have a regular bowel habit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Administration of any IMP within 12 weeks before entry to the study.&#xD;
&#xD;
          -  Use of any prescribed medication or St John's Wort within 14 days or OTC medication&#xD;
             within 5 days of dosing.&#xD;
&#xD;
          -  Existence of any surgical or medical condition which, in the judgement of the&#xD;
             investigator, might interfere with the absorption, distribution, metabolism or&#xD;
             excretion of the IMP.&#xD;
&#xD;
          -  History of any drug or alcohol abuse in the past 2 years, or alcohol consumption&#xD;
             greater than 21 units per week.&#xD;
&#xD;
          -  Presence or history of allergy requiring treatment.&#xD;
&#xD;
          -  Hayfever is allowed unless it is active or has required treatment within the previous&#xD;
             2 months.&#xD;
&#xD;
          -  Donation or loss of greater than 400 mL of blood within 12 weeks before entry to the&#xD;
             study.&#xD;
&#xD;
          -  Serious adverse reaction or serious hypersensitivity to any drug.&#xD;
&#xD;
          -  Presence of hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab) or HIV&#xD;
             1 or HIV 2 antibodies at screening.&#xD;
&#xD;
          -  Administration of radiolabelled substances or exposure to significant radiation (eg&#xD;
             serial x-ray or CT scans, barium meal etc) within the past 12 months.&#xD;
&#xD;
          -  Any ECG abnormality at screening (including QTc intervals of &gt;430 ms).&#xD;
&#xD;
          -  Past medical history of clinically significant ECG abnormalities, or a family history&#xD;
             of a prolonged QT interval syndrome.&#xD;
&#xD;
          -  Abnormal diet or substantial changes in eating habits within 30 days prior to study&#xD;
             initiation.&#xD;
&#xD;
          -  Treatment with any known enzyme altering agents (barbiturates, phenothiazines,&#xD;
             cimetidine, etc.) within 2 months prior to or during the study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stuart J Mair, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Syneos Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lindsay McGregor</last_name>
    <role>Study Director</role>
    <affiliation>Syneos Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charles River Laboratories Clinical Services Ltd, Origo Centre</name>
      <address>
        <city>Riccarton</city>
        <state>Edinburgh</state>
        <zip>EH14 4AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Lucero ML, Gonzalo A, Mumford R, Betanzos M, Alejandro A. An overview of bilastine metabolism during preclinical investigations. Drug Chem Toxicol. 2012 Jun;35 Suppl 1:18-24. doi: 10.3109/01480545.2012.682651. Review. Erratum in: Drug Chem Toxicol. 2012 Oct;35(4):472.</citation>
    <PMID>22616812</PMID>
  </reference>
  <reference>
    <citation>Lucero ML, Patterson AB. Whole-body tissue distribution of total radioactivity in rats after oral administration of [¹⁴C]-bilastine. Drug Chem Toxicol. 2012 Jun;35 Suppl 1:1-7. doi: 10.3109/01480545.2012.682650. Erratum in: Drug Chem Toxicol. 2012 Oct;35(4):472.</citation>
    <PMID>22616810</PMID>
  </reference>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>December 12, 2007</study_first_submitted>
  <study_first_submitted_qc>December 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2007</study_first_posted>
  <last_update_submitted>September 25, 2012</last_update_submitted>
  <last_update_submitted_qc>September 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mass Balance</keyword>
  <keyword>Metabolism</keyword>
  <keyword>Absorption</keyword>
  <keyword>Excretion</keyword>
  <keyword>Pharmacokinetics</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

